title: Peg-filgrastim versus filgrastim after autologous stem cell tranplantation: case-control study in patients with multiple myeloma and review of the literature.
abstract: We investigated the effects of a single s.c. injection of peg-filgrastim in 32 patients with multiple myeloma who underwent autologous stem cell transplantation (AuSCT) as first line treatment. For comparison, 32 myeloma patients with similar characteristics and receiving standard daily administration of filgrastim were matched. Overall, there were no statistically significant differences between peg-filgrastim and filgrastim in terms of tolerability, marrow recovery, severity of neutropenia, incidence and duration of febrile neutropenia, documented infections and transfusions. However, some favourable trends or effects in favour of peg-filgrastim were observed. This was confirmed by a review of the published papers about this topic.
authors.affiliation: Unit of Haematology and Stem Cell Transplantation, CROB, Centro di Riferimento Oncologico di Basilicata, Strada Provinciale, 8, 85028, Rionero in Vulture (Pz), Italy. p.musto@crob.it
authors.forename: Pellegrino
authors.initials: P
authors.lastname: Musto
authors.forename: Potito Rosario
authors.initials: PR
authors.lastname: Scalzulli
authors.forename: Elisabetta
authors.initials: E
authors.lastname: Terruzzi
authors.forename: Fausto
authors.initials: F
authors.lastname: Rossini
authors.forename: Pasquale
authors.initials: P
authors.lastname: Iacopino
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Messina
authors.forename: Roberto
authors.initials: R
authors.lastname: Guariglia
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Pietrantuono
authors.forename: Oreste
authors.initials: O
authors.lastname: Villani
authors.forename: Fiorella
authors.initials: F
authors.lastname: D'Auria
authors.forename: Antonietta
authors.initials: A
authors.lastname: Falcone
authors.forename: Grazia
authors.initials: G
authors.lastname: Sanpaolo
authors.forename: Maria Rosa
authors.initials: MR
authors.lastname: Valvano
authors.forename: Enrico Maria
authors.initials: EM
authors.lastname: Pogliani
authors.forename: Fortunato
authors.initials: F
authors.lastname: Morabito
mesh_terms: D016022:Case-Control Studies; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy / Q000601:surgery*; D011092:Polyethylene Glycols / Q000009:adverse effects / Q000627:therapeutic use*; D011994:Recombinant Proteins; D033581:Stem Cell Transplantation; D016896:Treatment Outcome
chemical_list: D011994:Recombinant Proteins; C486981:pegylated granulocyte colony-stimulating factor, human; D016179:Granulocyte Colony-Stimulating Factor; D011092:Polyethylene Glycols; D000069585:Filgrastim